Abstract
Lowering elevated blood pressure (BP) significantly prevented stroke in many clinical trials. However, most trials have not reported results specifically in primary stroke prevention. Fixed-effects, random-effects, and network meta-analyses were therefore performed to estimate the effectiveness of antihypertensive drug therapy, using all data available in the published literature. In the eight placebo-controlled trials that reported numbers of observed first strokes, active drug therapy reduced the risk of stroke by 31% (95% confidence interval: 21–40%, P < 0.0001). This estimate was quite similar to those obtained from a variety of meta-analyses that included either all, or various subsets of, 33 placebo-controlled trials in hypertensive patients (including those that enrolled patients with a prior stroke). The number of strokes prevented was significantly and directly related to the absolute risk of stroke in the placebo group. Among trials comparing active antihypertensive drugs, only five were primary prevention studies. Thus, insufficient power precludes reliable estimates of comparative efficacy of antihypertensive drug classes in primary stroke prevention. In network meta-analysis of all 61 trials involving 349,078 subjects (most of whom had hypertension, and some of whom had prior strokes), 75 pair-wise comparisons, and 11,599 strokes, all antihypertensive drug classes showed significant prevention of stroke, compared to placebo or no treatment, with an initial diuretic or calcium antagonist being more effective than other drug classes. Although some suggest that calcium antagonists have a small (but significant) BP-independent effect on stroke prevention, the preponderance of the evidence indicates lower achieved blood pressures result in greater stroke prevention.
Keywords
- Calcium Antagonist
- Antihypertensive Drug
- Antihypertensive Drug Therapy
- Stroke Prevention
- Recurrent Stroke
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. National High Blood Pressure Education Program Coordinating Committee. Hypertension. 2003;42:1206–52.
Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. The American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:1583–633.
Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics, 2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e1–161. Available on the Internet at: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.108.191261. Accessed 16 Dec 2008.
Lawes CMM, Van der Hoom S, Rodgers A. For the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.
Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. The INDANA project collaborators. Stroke. 1997;28:2557–62.
The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med. 2000;342:145–53.
Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699–702.
Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertension. 2003;21:875–86.
Trenkwalder P, Elmfeldt D, Hofman A, et al. For the Study on Cognition and Prognosis in the Elderly (SCOPE) Investigators. The Study on Cognition and Prognosis in the Elderly: major cardiovascular events and stroke in subgroups of patients. Blood Press. 2005;14:31–7.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA. 1967;202:1028–34.
Veterans Administration Cooperative Study Group on Antihypertensive Agents. II. Effects of treatment results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA. 1970;213:1143–52.
Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40(5 Suppl 1):198–05.
Helgeland A. Treatment of mild hypertension: a five-year controlled drug trial: the Oslo study. Am J Med. 1980;69:725–32.
The Australian Therapeutic. Trial in mild hypertension: report by the management committee. Lancet. 1980;1:1261–7.
Kuramoto K, Matsushita S, Kuwajima I, Murakami M. Prospective study on the treatment of mild hypertension in the aged. Japan Heart J. 1981;22:75–85.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: III. Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633–8.
Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity from the European working party on high blood pressure in the elderly trial. Lancet. 1985;1:1349–54.
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Brit Med J (Clin Res). 1985;291:97–104.
The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens. 1985;3:379–92.
Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145–51.
Perry HM Jr, Smith WM, McDonald RH, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke. 1989;20:4–13.
The SHEP Cooperative Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255–64.
Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–5.
MRC Working Party. Medical research council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–12.
Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens. 1996;14:1237–45.
Staessen JA, Fagard R, Thijs L, et al. for the Systolic Hypertension in Europe (Syst-EUR) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997;360:757–64.
Liu L, Wang J, Gong L, Liu G, Staessen JA. For the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823–9.
MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 2000;36:438–43.
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. Collaborative Study Group. N Engl J Med. 2001;345:851–60.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) Study Group. N Engl J Med. 2001;345:861–9.
Fox KM. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA study). Lancet. 2003;362:782–8.
Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the hypertension in the very elderly trial. J Hypertens. 2003;21:2409–17.
Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (The DIABHYCAR study). DIABHYCAR Study Investigators. BMJ. 2004;328:495.
Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. The PEACE Trial Investigators. N Engl J Med. 2004;351:2058–68.
Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. The ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) Investigators. J Hypertens. 2005;23:641–8.
Liu L, Zhang Y, Liu G, et al. for the FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–72.
Patel A. The ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.
Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431–9.
Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.
Yusuf S. For the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;371:1174–83.
Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main result from the HAPPHY trial. J Hypertension. 1987;5:560–72.
Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988;259:1976–82.
Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized trial. JAMA. 1996;276:785–91.
Agabiti-Rosei E, Dal Palù C, Leonetti G, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. The VHAS Investigators. J Hypertens. 1997;15:1337–44.
Schrier RW, Estacio RO. Additional follow-up from the ABCD Trial in patients with Type 2 diabetes and hypertension [letter]. N Engl J Med. 2000;343:1969.
Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:1779–80.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713–20.
Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–16.
National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium-antagonist and a diuretic in elderly hypertensives. Hypertension. 1999;34:1129–33.
Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–6.
Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–72.
Hansson L, Hedner T, Lund-Johansen P, et al. For the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–65.
Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. African American Study of Kidney Disease and Hypertension (AASK) Study Group. JAMA. 2001;285:2719–28.
Wright JT Jr, Bakris GL, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA. 2002;288:2421–31.
Dahlöf B, Devereux RB, Kjeldsen SE, et al. For the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
Zanchetti A, Bond M, Hennig M, et al. Calcium-antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation. 2002;106:2422–7.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. Second Australian National Blood Pressure Study Group. N Engl J Med. 2003;348:583–92.
Black HR, Elliott WJ, Grandits G, et al. for the CONVINCE Research Group. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA. 2003;289:2073–82.
Malacco E, Marcia G, Rappelli A, et al. Treatment of isolated systolic hypertension: the SHELL study results. The SHELL Investigators. Blood Pressure. 2003;12:160–7.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. The INVEST Investigators. JAMA. 2003;290:2805–16.
Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Disease-B (JMIC-B) randomized trial. Hypertens Res. 2004;27:181–91.
Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.
Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.
Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.
Ogihara T, Nakao K, Fukui T, et al. for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension. 2008;51:393–8.
Telmisartan, ramipril or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358:1547–9.
Jamerson K, Weber MA, Bakris GL, et al. for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.
Staessen JA, Wang J-G TL. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 01 March 2003. J Hypertension. 2003;21:1005–76.
Turnbull F. For the blood pressure lowering treatment trialists’ collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–35.
Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386–92.
Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.
Wang J-G, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37:1933–40.
Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699–703.
Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218–26.
Yusuf S, Diener H-C, Sacco RL, et al. for the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: the HOT study group. Lancet. 1998;351:1755–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Elliott, W.J. (2011). Blood Pressure Control and Primary Prevention of Stroke: Summary of Clinical Trial Data. In: Aiyagari, V., Gorelick, P. (eds) Hypertension and Stroke. Clinical Hypertension and Vascular Diseases. Humana Press. https://doi.org/10.1007/978-1-60761-010-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-60761-010-6_3
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-009-0
Online ISBN: 978-1-60761-010-6
eBook Packages: MedicineMedicine (R0)